Ensartinib (X-396) in ALK-Positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study.

Horn L, Infante JR, Reckamp KL, Blumenschein GR, Leal TA, Waqar SN, Gitlitz BJ, Sanborn RE, Whisenant JG, Du L, Neal JW, Gockerman JP, Dukart G, Harrow K, Liang C, Gibbons JJ, Holzhausen A, Lovly CM, Wakelee HA
Clin Cancer Res. 2018 24 (12): 2771-2779

PMID: 29563138 · PMCID: PMC6004248 · DOI:10.1158/1078-0432.CCR-17-2398

MeSH Terms (29)

Adult Aged Aged, 80 and over Anaplastic Lymphoma Kinase Animals Antineoplastic Agents Carcinoma, Non-Small-Cell Lung Cell Line, Tumor Disease Models, Animal Dose-Response Relationship, Drug Female Humans Immunohistochemistry In Situ Hybridization, Fluorescence Kaplan-Meier Estimate Lung Neoplasms Male Mice Middle Aged Mutation Neoplasm Grading Neoplasm Staging Piperazines Prognosis Protein Kinase Inhibitors Pyridazines Rats Treatment Outcome Young Adult

Connections (1)

This publication is referenced by other Labnodes entities:

Links